Supreme Court rules that "pay for delay" agreement restrains trade

06/18/2013

Yesterday the U.S. Supreme Court announced a 5-3 decision in FTC v. Actavis which ends the legal presumption that “pay for delay” agreements among branded and generic drug companies are legal. The decision will allow the FTC to challenge and block these agreements when it finds them to reduce competition from other generic drug companies. “While not unexpected, this decision effectively will shorten the patent protection period for many drugs, shortening the time a company can recoup its development costs,” said Coalition for Healthcare Communication Executive Director John Kamp. Read more.
Catch additional coverage of the decision from The Wall Street Journal, Reuters and CNBC.

View Full Article in:

http://www.cohealthcom.org/2013/06/18/update-supreme-court-decision-ends-presump...

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA